Linked e-resources
Details
Table of Contents
Cover
Medical Innovation and Disease Burden
Title
Copyright
Contents
Tables
Figures
Acknowledgements
Abbreviations
Introduction
Medical innovations and public health priorities
Health R&D in India
Public health relevance of medical R&D
1 Medical Innovation and Its Institutional Co-production in India
The Indian pharmaceutical industry: sales, export and R&D
Performance of the biopharmaceutical industry in India
The Indian medical device/technology sector
The institutional network of medical innovation
State, academia and industry linkages in India
Funding agencies and priority areas in medical innovation
Partnering institutions for clinical trials
Conclusion
Appendix 1A
2 The Disease Focus of Health Research and Development
R&D and disease focus
Disease focus of R&D in branded generics and biosimilars
Disease focus of therapeutic and vaccine R&D of biopharmaceuticals in India
R&D pipeline of major India biopharmaceuticals
Disease focus of new chemical entity research in India
Disease focus of medical device/technology R&D in India
Conclusion
Appendix 2A
Brief webnography of selected biopharmaceutical companies
3 Drug Development and Responsiveness to Disease Burden
Causes of deaths in India: a detailed analysis
Disease-specific mortality
Morbidity burden of diseases
Responsiveness of therapeutic drug development to disease burden
Implications of lower focus on infectious diseases
Responsiveness of vaccine development to the infectious disease burden
Conclusion
4 Affordability and the Social Divide
Drug price (de)regulation in India
The financial burden and affordability of medicines in India
Price variations of branded drugs
Price regulation and drug development: ongoing debates
Value-based pricing and the debate on price reduction in India
Technological innovation and cost of drugs
The social divide
Medicalisation, pharmaceuticalisation and social inequality
Conclusion
5 The Puzzle of Responsive and Responsible Medical Innovation
Challenges of responsive medical innovation
Actors, priorities and equity issues
Policy mismatches
Responsive and responsible innovation: the way ahead
Regulation with facilitation
Balancing the power in global R&D
Medical Innovation and Disease Burden
Title
Copyright
Contents
Tables
Figures
Acknowledgements
Abbreviations
Introduction
Medical innovations and public health priorities
Health R&D in India
Public health relevance of medical R&D
1 Medical Innovation and Its Institutional Co-production in India
The Indian pharmaceutical industry: sales, export and R&D
Performance of the biopharmaceutical industry in India
The Indian medical device/technology sector
The institutional network of medical innovation
State, academia and industry linkages in India
Funding agencies and priority areas in medical innovation
Partnering institutions for clinical trials
Conclusion
Appendix 1A
2 The Disease Focus of Health Research and Development
R&D and disease focus
Disease focus of R&D in branded generics and biosimilars
Disease focus of therapeutic and vaccine R&D of biopharmaceuticals in India
R&D pipeline of major India biopharmaceuticals
Disease focus of new chemical entity research in India
Disease focus of medical device/technology R&D in India
Conclusion
Appendix 2A
Brief webnography of selected biopharmaceutical companies
3 Drug Development and Responsiveness to Disease Burden
Causes of deaths in India: a detailed analysis
Disease-specific mortality
Morbidity burden of diseases
Responsiveness of therapeutic drug development to disease burden
Implications of lower focus on infectious diseases
Responsiveness of vaccine development to the infectious disease burden
Conclusion
4 Affordability and the Social Divide
Drug price (de)regulation in India
The financial burden and affordability of medicines in India
Price variations of branded drugs
Price regulation and drug development: ongoing debates
Value-based pricing and the debate on price reduction in India
Technological innovation and cost of drugs
The social divide
Medicalisation, pharmaceuticalisation and social inequality
Conclusion
5 The Puzzle of Responsive and Responsible Medical Innovation
Challenges of responsive medical innovation
Actors, priorities and equity issues
Policy mismatches
Responsive and responsible innovation: the way ahead
Regulation with facilitation
Balancing the power in global R&D